Cellerix is a biotechnology company actively developing and producing innovative medicines based on the use of stem cells of adult origin. The company is engaged in clinical PhaseII trials for the treatment of complex perianal fistulas. Cellerix was formally founded in 2004 as a Cell Therapy Company with sharp clinical focus and maintains a solid product pipeline, targeting main indications for fistula treatment and skin regeneration (Cx 501). One of Cellerix products (Cx 401) has reached Orphan Drug Status granted by EMEA and has already finished Phase II clinical trials, with very positive results. It is expected to begin Phase III trials in 2007. Cx501 has also reached this designation in May ’06 and is the second cell-therapy medicine to have been granted Orphan Status in Europe. Cellerix has strong expertise in clinical trials and regulatory issues related to Cell Therapy. The company has developed the only laboratory in Spain granted by the Spanish regulatory authorities for the production of cellular medicines.
Cellerix SL
Calle Marconi, 1
Parque Tecnológico de Madrid
Tres Cantos
28760 Madrid
Administration and General Services: cellerix@cellerix.com
R&D Departments: id@cellerix.com
Employment Opportunities: empleo@cellerix.com
Tel. 91 804 92 64
Fax. 91 804 92 63
